Leiomyosarcoma Clinical Trials

18 recruiting

Leiomyosarcoma Trials at a Glance

34 actively recruiting trials for leiomyosarcoma are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in Houston, Ann Arbor, and Paris. Lead sponsors running leiomyosarcoma studies include M.D. Anderson Cancer Center, National Cancer Institute (NCI), and Oslo University Hospital.

Browse leiomyosarcoma trials by phase

Treatments under study

About Leiomyosarcoma Clinical Trials

Looking for clinical trials for Leiomyosarcoma? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leiomyosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leiomyosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 2

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Estrogen Receptor Positive TumorEndometrial Stromal SarcomaUterine Sarcoma+6 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT07467772
Recruiting
Phase 1Phase 2

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

SarcomaSolid TumorLeiomyosarcoma+1 more
STORM Therapeutics LTD107 enrolled6 locationsNCT06975293
Recruiting
Phase 3

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Leiomyosarcoma
PharmaMar450 enrolled97 locationsNCT06088290
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 2

A Study of Ivonescimab in People With Leiomyosarcoma

Leiomyosarcoma
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07516925
Recruiting
Phase 3

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

LeiomyosarcomaRetroperitoneal SarcomaLiposarcoma
European Organisation for Research and Treatment of Cancer - EORTC250 enrolled164 locationsNCT04031677
Recruiting
Phase 2

Letrozole in Uterine Leiomyosarcoma

Uterine Leiomyosarcoma
GOG Foundation40 enrolled25 locationsNCT05649956
Recruiting
Phase 2

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Soft Tissue SarcomaLeiomyosarcoma of Ovary
Italian Sarcoma Group100 enrolled17 locationsNCT04383119
Recruiting
Phase 2

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

Uterine Leiomyosarcoma
M.D. Anderson Cancer Center48 enrolled1 locationNCT07076186
Recruiting
Phase 1

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Leiomyosarcoma
M.D. Anderson Cancer Center18 enrolled1 locationNCT06308419
Recruiting
Phase 3

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

LeiomyosarcomaSynovial SarcomaAlveolar Soft Part Sarcoma
Advenchen Laboratories, LLC325 enrolled24 locationsNCT03016819
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

SarcomaAngiosarcomaSoft Tissue Sarcoma (STS)+9 more
Royal Marsden NHS Foundation Trust800 enrolled1 locationNCT07432932
Recruiting
Not Applicable

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

AngiosarcomaOsteosarcomaEwing Sarcoma+4 more
Centre Leon Berard168 enrolled16 locationsNCT04055220
Recruiting

Localized Leiomyosarcoma Biomarker Protocol

Leiomyosarcoma
University of Michigan Rogel Cancer Center40 enrolled3 locationsNCT04925089
Recruiting
Phase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSynovial Sarcomas+7 more
Oslo University Hospital40 enrolled2 locationsNCT07173972
Recruiting
Phase 2

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Soft Tissue Sarcoma AdultLeiomyosarcomaSynovial Sarcomas+6 more
Oslo University Hospital110 enrolled4 locationsNCT07169344
Recruiting
Phase 2

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Metastatic LeiomyosarcomaUnresectable Leiomyosarcoma
Northwestern University29 enrolled1 locationNCT06571734